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Objectives: to evaluate the efficacy of conservative adjuvant therapy after revascularisation procedures in patients with
peripheral arterial disease.
Design: meta-analysis.
Materials: English-language studies published from 1976 to 1997.
Methods: reports on conservative therapies in patients with peripheral arterial disease after percutaneous transluminal
angioplasty, endarterectomy, thromboendarterectomy or bypass grafting were eligible. Uncontrolled or retrospective
studies, double reports or trials without clinical outcomes were excluded. Included studies were graded as level 1
(randomised and double- or assessor-blind), level 2 (open randomised), or level 3 (non-randomised comparative). (Loss
of) patency, amputation, vascular events and mortality were the outcomes considered. When feasible, end-of-treatment
results, either continuous or binary, were combined with appropriate statistical methods.
Results: thirty-two studies were included. Compared to non-active control, aspirin with dipyridamole improved (loss of)
patency (odds ratio (OR) 0.69, 95% confidence interval (CI), 0.53 to 0.90) and mortality (OR 0.80, 95% CI, 0.57 to
1.14); ticlopidine improved (loss of) patency (OR 0.53, 95% CI, 0.33 to 0.85) and amputation (OR 0.29, 95% CI, 0.08
to 1.01). Data on the effectiveness of vitamin-K inhibitors were not conclusive.
Conclusions: patients with peripheral arterial disease improve their outcome by receiving aspirin with dipyridamole or
ticlopidine after a revascularisation procedure.
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Introduction improving survival since they reduce the incidence of
myocardial infarction and stroke,12 which are the main
In Europe, the incidence of newly detected peripheral causes of death in these patients. However, their ef-
fectiveness, both for maintaining patency and pre-arterial disease reaches 1% per year after the age of
65. Within 10 years, up to 25% of the affected patients venting death in this group of patients, is debated.13–17
Therefore, we sought to evaluate the evidence com-will need revascularisation procedures.1–4 Without ad-
ditional treatment, reocclusion will occur in 20–60% ing from published clinical trials on the efficacy of any
prophylaxis in maintaining long-term arterial patencyof cases within 5 years of intervention.5–9
Rethrombosis and neointimal fibrous hyperplasia after revascularisation procedures (bypass-grafting,
percutaneous transluminal angioplasty, endarter-are considered the main pathogenic steps involved in
reocclusion.7 The use of anticoagulant or antiplatelets ectomy), as well as to assess the effect on survival.
agents represents a rational prophylactic approach in
order to improve the long-term patency of the re-
opened vessel.10 Moreover, since mortality in these
Materials and Methodspatients is increased, as compared to the general popu-
lation,11 antithrombotic agents have the potential of
We performed a Medline search on the English-
language medical literature, published from 1976 to
* Please address all correspondence to: B. Girolami, Dipartimento 1997, with the keywords ‘‘atherosclerosis, arterio-di Scienze Mediche e Chirurgiche, Universita` di Padova, Via Os-
pedale 105, 35100 Padova, Italy. sclerosis obliterans, peripheral vascular disease’’. In
1078–5884/99/040370+11 $35.00/0 Ó 2000 Harcourt Publishers Ltd.
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addition, references of articles and pertinent reviews Results
were evaluated to identify additional trials. Studies
were eligible for inclusion if they evaluated the efficacy Out of 51 potentially eligible studies, three were un-
controlled,21–23 eight were double reports,24–31 and eightof any prophylaxis after revascularisation procedures
in patients with peripheral arterial disease, regardless were retrospective;32–39 thus, 32 trials were left for
inclusion. Twenty-two studies compared an activeof Fontaine stage of disease18 and study design. Studies
on selected populations (diabetics, hypertensive, dys- treatment with a non-active control2,17,40–59 (Table 1);
one of these47 as well as 10 other studies13–16,60–65 evalu-lipidaemic patients), concerning analgesic treatment,
case reports, reviews and meta-analysis, were not ated two or more active drugs (Table 2).
eligible. The quality of this selection process was
evaluated using a random sample of one hundred
articles analysed by three independent operators
Active treatment versus non-active control(BG, EB, MHP) with a Kappa statistic ranging from
0.90 to 0.95.
Aspirin and dipyridamoleEligible studies were excluded if they were un-
Eleven studies evaluated the efficacy of aspirin versuscontrolled, duplicated other published material, were
control; seven were level 1,2,17,40–43,47 three were levelretrospective, or did not adequately assess at least
244,45,48 and one was a level 3 study,46 not further con-one of the following outcomes: mortality, cardio- or
sidered (Table 1). In nine studies,2,17,40–45,47 aspirin wascerebrovascular events, amputation, (loss of) patency,
administered in conjunction with dipyridamole, whilereocclusion, ankle–brachial index, walking distance,
in two studies it was administered alone.46,48side-effects. When feasible, reocclusions were con-
Eight studies evaluated the efficacy of aspirin (withverted to (loss of) patency rates.
dipyridamole) after infrainguinal bypass graft, twoThe included studies were graded by two in-
after percutaneous transluminal angioplasty and onedependent observers (BG, EB) for the quality of
after endarterectomy. In one study44 a bypass re-their design in the following categories: level 1
construction was performed in 60% of the enrolled(randomised, double- or single-blind or with blind
patients while the remaining 40% underwent end-assessment of the outcome), level 2 (open ran-
arterectomy. Another study17 enrolled patients afterdomised) and level 3 (non-randomised comparative)
percutaneous transluminal angioplasty of the commonstudies. Level 3 studies were considered for analysis
iliac, femoral and popliteal arteries.only if level 1 studies were not available. Since our
Sample sizes ranged from 49 to 549. Fontaine stagepurpose was to give a quantitative summary estimate
of disease18 ranged from I to IV, but in three studiesof treatment effect, the criterion used for inclusion
the exact stage was not reported.40,41,44 The daily dosein the final summary measure of efficacy was that
of aspirin varied from 50 to 990 mg, while the dailythe report enabled direct extraction or derivation of
dosage of dipyridamole ranged from 225 to 450 mg.the exact proportion of the outcome events in each
Control patients received placebo tablets in level 1group (in case of binary outcome measures), or of
studies, and no treatment at all in level 2 studies.a difference in effect between the treatment groups
Treatment duration ranged from the in-hospital periodand the common standard deviation (in case of
up to 51 months. The main outcomes evaluated in thecontinuous outcome measures). Extracted outcome
included trials were (loss of) patency, reocclusion,data were then summarised in tabular format, ex-
amputation, cardiovascular events and mortalitypressed as proportions or as means and standard
(Fig. 1).deviations, and, whenever possible and justifiable,
The end-of-treatment pooled results of level 1 stud-combined with appropriate statistical methods.19,20
ies, with regard to (loss of) patency after bypassThe statistical advisability of combining the results
graft, percutaneous transluminal angioplasty or end-of different trials was addressed with a statistical
arterectomy together, show an advantage for aspirin-test of heterogeneity, which considers whether dif-
with-dipyridamole-treated patients compared to con-ferences in treatment effect over individual trials are
trol (common OR 0.76, 95% CI, 0.58 to 0.99, p=0.04).consistent with natural variation around a constant
Although the test for heterogeneity was marginallyeffect. Results were expressed as (common) dif-
positive (p=0.034), all individual results of level 1ferences of the means or as (common) odds ratios,
studies are compatible with the estimate of the overallwith 95% confidence interval (CI). In case of dis-
treatment effect. When including the single level 2agreement at any step of the entire meta-analytical
study the treatment effect increased (common OR 0.69,process, consensus was reached with the help of a
third observer (MHP). 95% CI, 0.53 to 0.90, p=0.005) (Fig. 1).
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Table 1. Clinical trials evaluating the efficacy of antiplatelets, anticoagulants, physical training and smoking cessation compared to
non-active control in patients with peripheral arterial disease after revascularisation procedure.
Level* Sample† Stage‡ Procedure§ Site " Regimen¶ Duration
Aspirin and dipyridamole
After bypass graft
Green, 198240 1 32/17†† ns ptfe bg infra in 975–Dipyridamole 225 12 months
Kohler, 198441 1 44/44‡‡ ns asv/ptfe bg infra in 975+Dipyridamole 225 24 months
Goldman, 19842 1 22/31 II–IV d/ptfe bg fp 900+Dipyridamole 225 12 months
Donaldson, 198542 1 33/32 II d bg fp 990+Dipyridamole 225 12 months
McCollum, 199143 1 286/263 III–IV asv bg fp 600+Dipyridamole 300 36 months
Harjola, 198144 2 144/67§§ ns 60% bg, 40% ea supra a, ll "" 500–Dipyridamole 450 Hospital period
Clyne, 198745 2 70/70 II–III asv/ptfe bg fd 300+Dipyridamole 400 6 weeks
Satiani, 198546 3 93 (?/?) ns av, ptfe bg fp, d 650 1–51 months
After pta or ea
Heiss, 199047 1 122/67¶¶ I–III pta Mainly fp (300 or 990)+Dipyri- 6 months
damole 225
Bergqvist, 199417 1 108/115 II–IV pta ci, f, p 50+400 Dipyridamole 3 months (12
follow-up)
Lassilla, 199148 2 72/72 II–IV 90% ea, bg ns 250 3 months
Ticlopidine
Castelli, 198649 1 23/23 II–IV tea fp 500 6 months
Becquemin, 199750 1 122/121 IIb–IV asv bg fp, fd 500 24 months
Vitamin-K inhibitors
Arfvidsson, 199051 2 61/55 II–IV v/ptfe bg, tea fp, fd coumarin*** long term (6
years)
Kretschmer, 199252 2 66/64 II–IV rsv bg fp phenprocoumon††† long term (10
years)
Suloctidil
Mahler, 198753 1 48/51‡‡‡ II pta fp 600 12 months
Dextran 40
Rutherford, 198454 2 73/83 ns bg, te, tea, ea fp, infra p 75–100 ml/h iv§§§§ 3 days (1 week
follow-up)
PGE1
Gruß, 199755 2 42/41"""" III–IV pp, pta, ptfe/d bg deep f, af 60 lg/2 h iv bid 3 weeks (5 year
follow-up)
Physical training
Lundgren, 198856 2 25/25 II asv/ptfe bg, tea above knee exercise programme 6 months (12
follow-up)
Smoking cessation
Provan, 198757 3 107/187 II–IV asv/p bg abf, fp Quit smoke advice, 60 months
assessed with interview
Lassilla, 198858 3 53/125 II–IV bg, tea, pp ai, acf, fp Quit smoke advice, 36 months
assessed with interview
Powell, 199259 3 120/130 II–IV asv/p bg fp Quit smoke advice, 12 months
assessed with blood test
check
* Study level (see Methods).
† Total number of patients enrolled (active/control); in level 1 studies control patients received placebo, while in level 2 or level 3 studies,
they received nothing.
‡ Fontaine stage of disease; ns: not specified.
§ bg: bypass graft; pta: percutaneous transluminal angioplasty; ea: endarterectomy; te: thrombectomy; p: prosthetic; pp: profundaplasty;
ptfe: polytetrafluorethylene; d: Dacron; asv: autologous saphenous vein; rsv: reversed saphenous vein.
" a: aorta; f: femoral; bf: bifemoral; c: common; i: iliac; p: popliteal; d: distal; in: inguinal; cr: crural; ll: lower limb.
¶ Drug dosage is expressed in oral daily mg, unless differently stated; iv: intravenous; bid: bis in die.
†† 49 patients were randomised to daily receive aspirin 975 mg (16 patients), aspirin 975 mg and dipyridamole 225 mg (16 patients), or
placebo (17 patients); the first two groups were considered together in the analysis.
‡‡ Seven patients in each study group were reoperated on because of graft failure and were ‘‘randomised again’’; therefore 51 grafts for
each group were considered by the authors of the study for the final analysis.
§§ 283 patients were randomised into 4 groups to receive daily: aspirin 500 mg+dipyridamole 450 mg (93), aspirin 500 mg (92), dipyridamole
450 mg (93), no drug (86); the first 2 groups (144) compared with the last one (67) were considered in our analysis.
"" Patients who underwent supra–aortal intervention were excluded from our analysis.
¶¶ 199 patients were randomised to receive aspirin 300 mg daily plus dipyridamole 225 mg (56), aspirin 990 mg plus dipyridamole 225 mg
(66), or placebo (67); the first 2 groups are considered together versus placebo.
*** Prothrombin time 10–20%.
††† Prothrombin time 15–25%.
‡‡‡ Both groups received anticoagulant treatment.
§§§§ Subsequently all patients received antiplatelet therapy.
"""" All patients received oral aspirin, 500 mg daily (long-term), and subcutaneous calcium heparin 7500 IU twice daily (until discharge
from the hospital).
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Table 2. Clinical trials evaluating the efficacy of aspirin at different dosages or versus other active drugs in patients with peripheral
arterial disease after revascularisation procedure.
Author Level* Sample† Stage‡ Procedure§ Site" Aspirin¶ Comparison¶ Duration
Heiss, 199047 1 66/56†† I–III pta fp 990+Dipyridamole 225 Aspirin 300+Dipyri- 6 months
damole 225
Weichert, 199413 1 111/112 II–IV pta ll 1000‡‡ Aspirin 300‡‡ 6 months
Ranke, 199414 1 175/184 II–IV pta ai, fp 900 Aspirin 50 12 months
Minar, 199516 1 107/109 II–IV pta fp 1000 Aspirin 100 24 months
D’Addato, 199260"" 1 57/56 III–IV ptfe bg fp 900+Dipyridamole 225 Indobufen 400 12 months
Fisher, 198761 1 50§§/49 II–IV asv bg fp, cr 1500 PGE1 iv 0.2 ng/kg/min 10 days
Lucas, 198462 2 49/48 I–IV av, d bg; tea ai, fp 1050+Dipyridamole 150 Pentoxiphylline 1200 6 months
Raithel, 198763 2 59/59 IIb–IV p bg fp 1500+Dipyridamole 225 Pentoxiphylline 1200 12 months
Bollinger, 198564 2 81/39¶¶ II–IV ea fp 1000–Dipyridamole 225 Warfarin 24 months
Do, 199415 2 79/81 II–IV pta fp 50+Dipyridamole 400 Phenprocoumon*** 12 months
Edmondson, 199465 2 106/94 ns d, ptfe, v bg fp 900+Dipyridamole 300 Dalteparin 2500 IU 3 months
(12 follow-
up)
* Study level (see Methods).
† Total number of patients enrolled (active/control).
‡ Fontaine stage of disease; ns: not specified.
§ bg: bypass graft; pta: percutaneous transluminal angioplasty; ea: endarterectomy; p: prosthetic; ptfe: polytetrafluoroethylene; d: Dacron;
v: vein.
" f: femoral; a: aorta; i: iliac; p: popliteal; cr: crural; ll: lower limb.
¶ Expressed in oral daily mg, unless differently stated.
†† 199 patients were randomised to receive daily aspirin 990 mg plus dipyridamole 225 mg (66 patients), aspirin 300 mg plus dipyridamole
225 mg (56) or placebo (67); the former two groups are considered for the comparative analysis.
‡‡ Both groups received heparin up to 5 days after the intervention.
§§ Two patients had thromboangiitis obliterans; both groups also received subcutaneous or intravenous 15 000 IU heparin for 10 days.
"" A seven days’ wash-out period preceded the active drug administration.
¶¶ Patients were randomised to receive daily aspirin 1000 mg alone (40 patients), aspirin 1000 mg plus dipyridamole 225 mg (41), warfarin
(39); the first two groups are considered together for the analysis; warfarin was monitored by patient’s physicians; mean prothrombin
time 34%.
*** Prothrombin time (INR) 2.3–0.8.
With regard to the effects of aspirin with di- observed in actively treated patients, although the
difference did not reach statistical significance (com-pyridamole after bypass graft only, six studies2,40–44
reported (loss of) patency results at the end of treat- mon OR 0.80, 95% CI, 0.57 to 1.14, p=0.2) (Fig. 1).
ment, while five studies2,40–43 reported these results at
12 months (raw data not shown). Both analyses showed Ticlopidine
Two level 1 studies were included49,50 (Table 1). Samplean advantage for actively treated patients (common
OR 0.72, 95% CI, 0.53 to 0.99, p=0.05, and common size ranged from 46 to 243 patients, belonging to
Fontaine II to IV stage of disease and treated withOR 0.76, 95% CI, 0.50 to 0.85, p=0.002, respectively).
The efficacy of aspirin with dipyridamole on (loss thromboendarterectomy49 or autologous saphenous
bypass graft.50 With regard to (loss of) patency, pooledof) patency after percutaneous transluminal an-
gioplasty or endarterectomy was evaluated in two end-of-treatment results49,50 show a statistically sig-
nificant advantage in favour of actively treated patientslevel 1 studies.17,47 After 6 months of treatment a trend
in favour of aspirin-plus-dipyridamole-treated (common OR 0.53, 95% CI, 0.33 to 0.85, p=0.009) (Fig.
1).patients was observed (OR 0.66, 95% CI, 0.42 to 1.04;
p=0.075) (raw data not shown). Pooled end-of-treat- According to one study,50 ipsilateral amputation was
reduced in the ticlopidine-treated patients (OR 0.29,ment obervations show an advantage for aspirin-plus-
dipyridamole-treated patients (common OR, 0.63, 95% 95% CI, 0.08 to 1.01, p=0.052) (Fig. 1). End-of-treatment
pooled results do not show differences in terms ofCI, 0.40 to 0.98, p=0.04).
Three studies provided data on amputation rates at death between ticlopidine- and placebo-treated
patients49,50 (Fig. 1).the end of follow-up after a graft procedure43,45 or after
percutaneous transluminal angioplasty.17 The dif-
ference observed between the groups was not stat- Vitamin K inhibitors
Two level 2 studies were included51,52 (Tale 1). Sampleistically significant (Fig. 1). Data on mortality were
available from five level 12,17,40,41,43 and two level 2 sizes ranged from 116 to 130; enrolled patients be-
longed to Fontaine II to IV stage of disease, andstudies.45,48 Pooling data, a reduction in mortality was
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Fig. 1. Effect of aspirin with dipyridamole, ticlopidine and vitamin-K inhibitors compared to non-active control on (loss of) patency,
amputation, and mortality, in patients with peripheral arterial disease and treated with revascularisation procedures; end-of-treatment
results are expressed as odds ratio with 95% confidence interval, for individual and combined studies.
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Table 3. Efficacy of suloctidil, dextran, PGE1, physical training and smoking cessation, compared to non-active control, as adjunct
conservative treatment in patients with peripheral arterial disease after revascularisation procedures.
Author Level* Results
Suloctidil
Mahler, 198753 1 Patency, stenosis and mortality were not different compared to control
Dextran 40
Rutherford, 198454 2 Occlusion, myocardial infarction and mortality were not different compared to control
PGE1
Gruß, 199755 2 Remission to stage IIb was higher in the actively treated patients (OR 2.8, 95% CI, 1.1–7.6), as
well as the reduction in major amputations (OR 0.4, 95% CI, 0.13–1.02); survival was not
significantly improved in the PGE1 group
Physical training
Lundgren, 198856 2 The supervised exercise programme significantly improved pain-free walking distance of 154 m
(95% CI 74–382) compared to control; total walking distance, ankle–brachial index, calf blood
flow and mortality were not different
Smoking cessation
Provan, 198757 3 Compared to control, 5 year cumulative patency resulted higher in patients who quitted smoking
and with aortobifemoral graft (77% vs. 42%, p<0.001) or prosthetic femoropopliteal graft (43% vs.
19%, p<0.05), not in patients with femoropopliteal vein grafts
Lassilla, 198858 3 Amputation and local ‘‘lower limbs adverse events’’ (†) were reduced in the quitting smoking
group (OR, respectively, 0.11, 95% CI 0.02–0.85, p=0.03, and 0.43, 95% CI 0.2–0.93); mortality and
‘‘central adverse events’’ (‡) were not different compared to current smokers
Powell, 199259 3 One-year patency was improved by quitting smoking both with vein (84% vs. 63%, p<0.02) or
prosthetic grafts (87% vs. 68%, p=0.025)
* Study level (see Methods).
† Lower limbs adverse events: deterioration of peripheral arterial disease, ankle–brachial index decrease of 0.1 or more, Fontaine-stage
worsening, major amputation, vascular reconstructive procedure.
‡ Central adverse events: angina pectoris, acute myocardial infarction, sudden heart failure, transitory ischaemic attack, stroke;
vs. versus.
underwent bypass-grafting or thrombo- Other interventions
Of the other interventions (suloctidil, dextran, PGE1,endarterectomy of the femoropopliteal or femorodistal
arteries. Anticoagulant treatment was administered physical training, smoking cessation) only a limited
number of trials were available,53–59 or the results werelong term in both studies (Table 1) for a mean pro-
thrombin time ranging from 10 to 25%. presented in such a way that data extraction was
impossible. Main results are summarised in Table 3.Both studies51,52 reported results on (loss of) patency.
End-of-treatment pooled results do not show any dif-
ference between treated and control patients (common
OR 0.96, 95% CI 0.39–2.35) (Fig. 1). However, in these
Studies comparing active drugsstudies an advantage for the use of vitamin K inhibitors
was observed after 6 months, 1 and 4 years of treatment
Aspirin – high versus low doseafter the vascular procedure (common OR 0.29, 95%
Four level 1 studies were included13,14,16,47 (Table 2) andCI 0.1–0.80, p=0.02; 0.58, 95% CI 0.35–0.98, p=0.04;
main results are summarised in Table 4. In general,and 0.46, 95% CI 0.24–0.88, p=0.02, respectively) (raw
different dosages of aspirin were equally effectivedata not shown).
with regard to (loss of) patency, reocclusion and am-Amputation rate, according to one study,52 was stat-
putation. Side-effects (mainly gastrointestinal) wereistically significantly lowered in the treated patients
significantly more frequent with higher dosages ofafter 10 years (OR 0.25; 95% CI from 0.06 to 0.91; p=
aspirin.14,160.016). In the other study51 the cumulative limb salvage
after 36 months was not different between the two
groups (log rank p=0.81). Mortality was almost sig- Aspirin with dipyridamole versus other active drugs
Aspirin was compared with indobufen,60 prostaglandinnificantly reduced in the actively treated patients (Fig.
1) according to one study52 (OR 0.51, 95% CI 0.24–1.08, E161 pentoxiphylline,62,63 vitamin-K inhibitors,15,64 and
dalteparin.65 Dipyridamole was added to aspirin in allp=0.08). The other study51 showed no difference with
regard to the cumulative survival rate after 48 months studies but one.61 Study details and main results are
summarised in Tables 2 and 4 and in Figure 2. In one(50% versus 62%, log-rank test p=0.51).
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Table 4. Efficacy of aspirin compared with different dosages or with other active drugs in the adjunct conservative treatment of
patients with peripheral arterial disease after revascularisation procedures.
Author Level* Results (expressed as relative effect of first versus second drug)
High vs. low aspirin dosage
Heiss, 199047 1 Patency was not different
Weichert, 199413 1 Reocclusion, mortality and (mainly gastric) side-effects were not
different
Ranke, 199414 1 Gastroenteric side-effects were higher in the high-dose group (OR 3.9,
95% CI 1.2–13, p=0.03); patency and mortality were not different
Minar, 199516 1 Gastroenteric side-effects were significantly higher in the high-dose
aspirin group (OR 6.0, 95% CI 1.9–21.7, p=0.001); patency, amputation
and mortality were not different
Aspirin with dipyridamole vs. indobufen
D’Addato, 199260 1 No significant differences in terms of patency (OR 0.68, 95% CI
0.33–1.42), mortality and gastrointestinal bleedings (OR 7.4, 95% CI
0.46–119.7)
Aspirin vs. PGE1
Fisher, 198761 1 Amputation was higher in the aspirin-treated patients (OR 6.2, 95% CI
from 1.2 to 31.2, p=0.03), while reocclusion was not different
Aspirin with dipyridamole vs. pentoxiphylline
Lucas, 198462 2 Reocclusion, amputation, mortality, PFWD, ABI and side-effects were
not different
Raithel, 198763 2 Patency, amputation, mortality were not different; gastrointestinal side-
effects were significantly lower in the pentoxiphylline group (OR 11.2,
95% CI 5.1–25.0, p<0.0001)
Aspirin with dipyridamole vs. dalteparin
Edmondson, 199465 2 Patency and mortality were lower in the aspirin group compared to the
dalteparin-treated patients (respectively, 64.1% vs. 79.5%, log-rank test
p=0.02, and OR 0.2, 95% CI 0.07–0.8) (different mortality was explained
by cancer imbalance between the two groups)
* Study level (see Methods);
vs.=versus.
study,60 gastrointestinal bleedings were lower in the studies. Patency was statistically significantly im-
indobufen-treated patients compared to those treated proved by aspirin with dipyridamole or by ticlopidine.
with aspirin plus dipyridamole, while in another study,15 Vitamin-K inhibitors improved patency at 1 and 4
severe bleedings were more frequent in the phen- years, but not at the end of follow-up. Amputation
procoumon-treated patients (OR 0.1, 95% CI, 0.001 rates were reduced by ticlopidine50 and by vitamin-K
to 2.2) compared to those treated with aspirin plus inhibitors.52 Mortality was reduced by aspirin plus
dipyridamole (Table 4). dipyridamole, although statistical significance was not
reached (Fig. 1). Ticlopidine is likely to improve sur-
vival, by analogy with other studies66 which consider
patients only at stage II of disease, according to Fon-Discussion
taine.18 With regard to vitamin-K inhibitors, results
were not conclusive. The two level 2 studies thatIt is common clinical practice to prescribe adjuvant
directly compared aspirin plus dipyridamole with vit-treatments in order to prevent reocclusion after re-
amin-K inhibitors were small in size and producedvascularisation procedures in patients with peripheral
inconsistent results.15,64 Patency seemed improved inarterial disease. Although many different strategies
the aspirin plus dipyridamole compared to vitamin-K-have long been available for this purpose, only aspirin,
inhibitor-treated patients (Fig. 2), while no differencesassociated with dipyridamole, and ticlopidine have
were observed in terms of amputation and mortality.been extensively evaluated with methodologically
Aspirin associated with dipyridamole was also com-sound studies. Oral anticoagulants were evaluated in
pared in several small studies with other active drugs.two level 2 studies and other strategies (suloctidil,
Indobufen was as effective as aspirin in terms ofdextran, PGE1, physical training and smoking ces-
sation) were merely evaluated in single or level 3 patency, while mortality and gastrointestinal bleedings
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Fig. 2. Effect of aspirin with dipyridamole compared to vitamin-K inhibitors on (loss of) patency, amputation, and mortality, in patients
with peripheral arterial disease and treated with revascularisation procedures; end-of-treatment results are expressed as odds ratio with
95% confidence interval, for individual and combined studies.
were not significantly different among the two The Antiplatelet Trialists’ Collaboration meta-ana-
lysis67 demonstrated a significant 43% occlusion-rategroups.60 The comparison with pentoxiphylline62,63 was
evaluated in only two level 2 studies and failed to reduction in patients treated with antiplatelets because
of arterial disease, as compared to control patients.show any difference with regard to efficacy, and was
inconsistent for the occurrence of side-effects. Prosta- This figure is in agreement with our results restricted
to patients who received revascularisation proceduresglandin E1 was superior to aspirin alone in preventing
amputation within 10 days.61 Three months of sub- because of peripheral arterial disease. However, such
evidence is available only for aspirin associated withcutaneous dalteparin significantly improved 1-year
patency after graft surgery in comparison to aspirin.65 dipyridamole, and for ticlopidine; a similar positive
effect can be only speculated on for other antiplateletsFour level 1 studies showed that decreasing aspirin
dosage significantly lowers side-effects without dis- drugs inclusive of aspirin alone and should be evalu-
ated in large properly designed trials. Furthermore,advantages in terms of efficacy.13,14,16,47
Among the other drugs that were compared with a the Antiplatelet Trialists’ Collaboration meta-analysis12
definitely also demonstrated a statistically significantcontrol group, only the results of PGE1 (limb survival
and Fontaine stage improvement) and supervised 25% reduction of vascular events (vascular death, non-
fatal myocardial infarction or stroke) and a 17% re-physical training (improved pain-free walking dis-
tance) were promising. Quitting smoking improved duction of total mortality in patients at high cardio-
vascular risk (including patients with peripheralpatency and amputation rate in level 3 studies.
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